What is Ozanimod? Quick Facts about New IBD Treatment
Ozanimod is a new medication for chronic inflammatory diseases currently in Phase 3 clinical trials as an IBD treatment.
Quick facts about Ozanimod
Developed by: The Scripps Research Institute, partnered with Celgene
Conditions: various autoimmune conditions; multiple sclerosis, Crohn’s disease, ulcerative colitis
Drug type: sphingosine 1-phosphate 1 (S1PR1) receptor antagonist
Administration: trials have examined both oral and injected doses
How It Works: Ozanimod inhibits the receptor of a protein called S1PR1. Among other functions, S1PR1 regulates the growth and transport of lymphocytes (immune cells). By inhibiting S1PR1, Ozanimod decreases lymphocytes in the gastrointestinal tract, modifying the immune response.
For IBD patients who have experienced failure with anti-TNF treatments such as Humira, Simponi, Cimzia, and Remicade, research is showing Ozanimod to be a promising alternative IBD treatment option. Some of the available data compares Ozanimod to conventional anti-TNF treatments—in comparing Ozanimod's action of suppressing inflammatory cytokines and reducing lymphocytes, researchers have concluded that the new medication demonstrates robust efficacy when compared to conventional anti-TNF therapies.
In a Phase 2 study called the TOUCHSTONE study, researchers examined the effects of Ozanimod in approximately 200 patients with ulcerative colitis. At 8 months, the remission rate in the placebo group was 6%, while remission rates for patients taking Ozanimod were 21% and 26% (two groups taking different doses).
Find Your Treatment
See what treatments are right for you by answering a couple questions.
What condition do you have?Crohn's Disease Ulcerative Colitis
Ozanimod Clinical Trials for IBD
Ozanimod entered into Phase 3 clinical trials for Crohn’s disease in early 2018 and is already in Phase 3 clinical trials for ulcerative colitis.
It is expected to first hit the market for multiple sclerosis in late 2018, with approval as an IBD treatment to follow.
Signing up for IBD Clinical Trials: Ozanimod
In Phase 3 clinical trials, a medication is already known to be well-tolerated and effective. Patients who participate in Phase 3 clinical trials for IBD treatments may be helping the researchers to measure the medication’s efficacy, dosing, and other other metrics.
Many patients who join clinical trials for Crohn’s disease or colitis have already tried several IBD treatment options with limited success. For these patients, joining a clinical trial can provide early access to innovative treatments, in addition to consultation with dedicated inflammatory bowel disease specialists.
Clinical Trials at the University of Chicago Medicine
At Discover Therapies, we connect IBD patients with clinical trials in various locations throughout North America, with many trials held at dedicated inflammatory bowel disease centres run by IBD specialists.
An example of these dedicated research clinics is the University of Chicago Medicine, where Dr. Russell Cohen is heading the Ozanimod clinical trials. In addition to serving as the principal investigator on several other studies on intravenous IBD treatments, Dr. Cohen an active researcher, clinical doctor, and author of Inflammatory Bowel Disease: Diagnosis and Therapeutics, a leading textbook in the IBD field.
One main reason why patients participate in clinical trials is that they gain access to professionals like Dr. Cohen who are up to date on the latest innovations in IBD research and clinical practice. To determine your eligibility for clinical trials, sign up for Ozanimod, start by taking a short quiz on the Discover Therapies.
(2018). Ozanimod Successful in Clinical Trials for Multiple Sclerosis. The Scripps Research Institute. Retrieved from https://www.scripps.edu/news/press/2017/20171109ozanimod.html
Scott, F. L., Clemons, B., Brooks, J., Brahmachary, E., Powell, R., Dedman, H., … Peach, R. J. (2016). Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P1) and receptor‐5 (S1P5) agonist with autoimmune disease‐modifying activity. British Journal of Pharmacology, 173(11), 1778–1792. http://doi.org/10.1111/bph.13476
Tran, J. Q., Hartung, J. P., Peach, R. J., Boehm, M. F., Rosen, H., Smith, H., … Frohna, P. A. (2017). Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator. Journal of Clinical Pharmacology, 57(8), 988–996. http://doi.org/10.1002/jcph.887